T. Rowe Price Associates’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-103,915
| Closed | -$316K | – | 3099 |
|
|
2024
Q4 | $316K | Buy |
103,915
+7,839
| +8% | +$34.1K | ﹤0.01% | 2487 |
|
|
2024
Q3 | $499K | Buy |
96,076
+1,623
| +2% | +$8.07K | ﹤0.01% | 2240 |
|
|
2024
Q2 | $243K | Buy |
94,453
+25,092
| +36% | +$85.7K | ﹤0.01% | 2514 |
|
|
2024
Q1 | $342K | Buy |
69,361
+15,496
| +29% | +$91.7K | ﹤0.01% | 2375 |
|
|
2023
Q4 | $474K | Buy |
53,865
+3,487
| +7% | +$28.6K | ﹤0.01% | 2197 |
|
|
2023
Q3 | $578K | Buy |
50,378
+4,838
| +11% | +$93K | ﹤0.01% | 2038 |
|
|
2023
Q2 | $1.15M | Buy |
45,540
+2,747
| +6% | +$85.6K | ﹤0.01% | 1735 |
|
|
2023
Q1 | $1.38M | Sell |
42,793
-572
| -1% | -$17.8K | ﹤0.01% | 1627 |
|
|
2022
Q4 | $801K | Sell |
43,365
-610
| -1% | -$14K | ﹤0.01% | 1888 |
|
|
2022
Q3 | $1.19M | Buy |
43,975
+5,643
| +15% | +$114K | ﹤0.01% | 1672 |
|
|
2022
Q2 | $530K | Buy |
38,332
+428
| +1% | +$6.59K | ﹤0.01% | 2202 |
|
|
2022
Q1 | $739K | Buy |
37,904
+5,551
| +17% | +$84.2K | ﹤0.01% | 2164 |
|
|
2021
Q4 | $528K | Buy |
32,353
+7,608
| +31% | +$127K | ﹤0.01% | 2361 |
|
|
2021
Q3 | $689K | Buy |
24,745
+200
| +0.8% | +$5.71K | ﹤0.01% | 2227 |
|
|
2021
Q2 | $728K | Buy |
24,545
+2,303
| +10% | +$66.4K | ﹤0.01% | 2205 |
|
|
2021
Q1 | $622K | Sell |
22,242
-6,904
| -24% | -$191K | ﹤0.01% | 2262 |
|
|
2020
Q4 | $826K | Buy |
29,146
+6,836
| +31% | +$177K | ﹤0.01% | 2020 |
|
|
2020
Q3 | $561K | Buy |
22,310
+2,610
| +13% | +$68.4K | ﹤0.01% | 2046 |
|
|
2020
Q2 | $481K | Buy |
19,700
+561
| +3% | +$11.1K | ﹤0.01% | 2062 |
|
|
2020
Q1 | $283K | Buy |
19,139
+2,896
| +18% | +$59.9K | ﹤0.01% | 2208 |
|
|
2019
Q4 | $264K | Sell |
16,243
-11,350
| -41% | -$176K | ﹤0.01% | 2353 |
|
|
2019
Q3 | $359K | Buy |
27,593
+247
| +0.9% | +$3.02K | ﹤0.01% | 2226 |
|
|
2019
Q2 | $355K | Buy |
27,346
+139
| +0.5% | +$1.75K | ﹤0.01% | 2250 |
|
|
2019
Q1 | $429K | Buy |
27,207
+13,362
| +97% | +$232K | ﹤0.01% | 2174 |
|
|
2018
Q4 | $279K | Buy |
+13,845
| New | +$305K | ﹤0.01% | 2316 |
|
Other funds holding RVNC
T. Rowe Price Associates's RVNC Position: Q1 2025 in Review
T. Rowe Price Associates sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 103,915 shares — an estimated $316K sold.
T. Rowe Price Associates first reported a position in RVNC in Q4 2018 and held it in 25 quarters. The position peaked at $1.38M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- T. Rowe Price Associates reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- T. Rowe Price Associates sold 103,915 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $316K.
- T. Rowe Price Associates first reported a position in Revance Therapeutics, Inc. in Q4 2018 and held it in 25 quarters.
- T. Rowe Price Associates's Revance Therapeutics, Inc. position peaked at $1.38M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on T. Rowe Price Associates's 13F filing for Q1 2025, filed 14 May 2025.